Record second quarter 2026 revenue increased 35% to $17.1 million, compared with Q2 2025
Adjusted EBITDA more than doubled year-over-year to $3.5 million, with margin expanding to 20%
Remaining performance obligations grew 30% year-over-year to $80.4 million
Shipped a record total 125 Deep TMS systems in Q2 2026, a 42% increase year-over-year
Raises FY 2026 revenue and EBITDA guidance
BURLINGTON, Mass. and JERUSALEM, Aug. 12, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported its second quarter 2026 financial results and provided an operational update.
Recent Financial and Operational Highlights
-- Revenue in the second quarter of 2026 increased 35% to $17.1 million,
compared with $12.6 million in the second quarter of 2025.
-- Remaining performance obligations (RPOs) rose to $80.4 million as of June
30, 2026, a 30% increase compared with the same period last year.
-- Shipped a record total 125 Deep TMS$(TM)$ systems during the second quarter
of 2026, a 42% increase compared with the same period last year. Total
installed base now stands at approximately 1,949.
-- Operating income for the second quarter of 2026 increased more than 300%
to $2.4 million, compared with $0.6 million for the prior year period.
Operating margin for the quarter expanded to 14% from 5% for the prior
year period.
-- Adjusted EBITDA for the second quarter of 2026 increased 141% to $3.5
million, compared with $1.5 million for the prior year period. Adjusted
EBITDA margin for the quarter expanded to 20% from 11% for the prior year
period.
-- Net income for the second quarter of 2026 increased 34% to $2.7 million,
compared with $2.0 million for the prior year period.
-- As of June 30, 2026, cash and cash equivalents and restricted cash
totaled $62.4 million, an increase of approximately 6% compared with
March 31, 2026.
-- Generated $6.3 million of cash flow from operations during the second
quarter of 2026.
-- Continued expansion of insurer coverage for the SWIFT(TM) (Short-course
with Intrinsic Field Targeting) accelerated Deep TMS protocol.
-- Presented real-world data in patients with comorbid post-traumatic stress
disorder (PTSD) and major depressive disorder (MDD), demonstrating an
83.5% response rate in PTSD symptoms, with a mean 52% reduction in PCL-5
scores.
-- Presented the first prospective 12-month durability data for the SWIFT
accelerated Deep TMS protocol at the 14th Annual Clinical TMS Society
(CTMSS) Meeting, demonstrating sustained clinical improvement through one
year following treatment.
-- Continued expanding the Company's growing minority investment portfolio
through strategic investments in Hopemark Health and Radial Health, with
several previous portfolio investment targets indicating significant
growth in patient access to care due to the growth capital afforded under
the program.
Updated Full-Year 2026 Financial Guidance
The Company now expects to report for the full-year ended December 31, 2026:
-- Revenue of $68 million to $70 million, compared to the previous range of
$66 to $68 million. The updated revenue guidance represents anticipated
growth of approximately 30% to 34% compared with revenue for 2025.
-- Operating income of 13.5% to 14% of revenue, compared to the previous
range of 13%-14%.
-- Adjusted EBITDA of $13 million to $14 million, compared to the previous
range of $12 million to $14 million. The updated Adjusted EBITDA guidance
represents anticipated growth of approximately 90% to 100% over 2025.
"This quarter marked our second consecutive quarter of approximately 35% revenue growth and further expansion in operating leverage. Revenue reached a record $17.1 million, Adjusted EBITDA more than doubled to $3.5 million, and we generated more than $6.0 million of operating cash flow. Record system shipments and RPO of $80.4 million further strengthen our visibility into continued growth," said Hadar Levy, Chief Executive Officer of BrainsWay. "We are seeing strong momentum across the business, which is fueled by expanding reimbursement coverage and increasing utilization throughout our installed base. As a result, we are raising our full-year financial guidance for 2026."
Call and Webcast
BrainsWay's management will host a conference call in English on Wednesday, August 12, 2026, at 8:30 a.m. Eastern Daylight Time (EDT) to discuss these results and answer questions, followed by a webinar hosted in Hebrew on Thursday, August 13, 2026, at 11:00 AM Israel Daylight Time $(IDT)$. All details to access these events are listed below.
In English:
-- Date: Wednesday, August 12, 2026
-- Time: 8:30 AM EDT
-- Dial-In: 1-877-269-7751 (U.S) / 1-201-389-0908 (International)
-- Conference ID: 13761391
-- The U.S. conference call will be broadcast live and will be available for
replay for 30 days on the Company's website at investors.brainsway.com
and through this link:
https://viavid.webcasts.com/starthere.jsp?ei=1768433&tp_key=0923ccd15a
In Hebrew:
-- Date: Thursday, August 13, 2026
-- Time: 11:00 AM IDT
-- To register for this webinar, please click here: BrainsWay Q2 2026 IL
Investor Webinar
Non-IFRS Financial Measures
In addition to our results determined in accordance with International Financial Reporting Standards (IFRS), including in particular operating profit and net profit, we believe that Adjusted EBITDA, a non-IFRS measure, is useful in evaluating our operating performance. We define Adjusted EBITDA as net profit adjusted for depreciation and amortization, finance income, finance expenses, income taxes, cost of share-based payments, and one-time restructuring and litigation expenses.
In addition to operating income (loss) and net income (loss), we use Adjusted EBITDA as a measure of operational efficiency. We believe that this non-IFRS financial measure is useful to investors for period-to-period comparisons of our business and in understanding and evaluating our operating results for the following reasons:
-- Adjusted EBITDA is widely used by investors and securities analysts to
measure a company's operating performance without regard to items such as
stock-based compensation expenses, depreciation and amortization, finance
expenses, income taxes, and certain one-time items such as restructuring
and litigation expenses, that can vary substantially from company to
company depending upon their financing, capital structures and the method
by which assets were acquired.
-- Our management uses Adjusted EBITDA in conjunction with IFRS financial
measures for planning purposes, including the preparation of our annual
operating budget, as a measure of operating performance and the
effectiveness of our business strategies and in communications with our
board of directors concerning our financial performance; and Adjusted
EBITDA provides consistency and comparability with our past financial
performance, facilitates period-to-period comparisons of operations, and
also facilitates comparisons with other peer companies, many of which use
similar non-IFRS or non-GAAP financial measures to supplement their IFRS
or GAAP results.
Adjusted EBITDA, however, should not be considered as an alternative to operating profit (loss) or net profit (loss) for the period and may not be indicative of the historic operating results of the Company; nor is it meant to be predictive of potential future results. Adjusted EBITDA is not a measure of financial performance under IFRS and may not be comparable to other similarly titled measures for other companies. A reconciliation between the Company's net profit (loss) and Adjusted EBITDA is presented in the attached summary financial statements.
Because of these and other limitations, you should consider Adjusted EBITDA along with other IFRS-based financial performance measures, including net profit (loss) and our IFRS financial results.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS(TM)) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Forward-Looking Statements
Comments